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Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are the most common primary malignancies arising in the liver. Hepatocellular carcinoma is the fifth most common adult cancer and the second leading cause of cancer-related 
death globally, while cholangiocarcinoma is the second most prevalent primary liver cancer.
There are a number of benign and malignant liver lesions that can mimic HCC and ICC 
on diagnostic imaging of the liver (Table). Careful review of the clinical history, physical 
examination, hepatitis serology and imaging studies are helpful to narrow down differential 
diagnoses. Accurate characterization of benign lesions is important to avoid misdiagnosing 
them as cancers, which may lead to unwarranted surgery or intervention. 
Accurate imaging diagnosis is particularly important in the context of patients with high 
risk for developing HCC, namely cirrhosis and chronic viral Hepatitis B or C, because treat-
ment can be instituted without a histopathological diagnosis if the characteristic features of 
arterial hyper-enhancement and washout appearance are detected (1). 
The liver imaging reporting and data systems (LI-RADS) document outlines several an-
cillary features that would favor HCC or malignancy. These ancillary features should also 
be carefully sought out in the evaluation of a nodule. Failure to adhere to well-established 
guidelines such as LI-RADS may result in the erroneous diagnosis and treatment of non-
HCC lesions. To address this, radiologists should first exclude benign entities such as cysts, 
hemangiomas and arterioportal shunts. A liver mass with a targetoid appearance is denot-
ed as LR-M in LI-RADS as it is likely to represent an adenocarcinoma rather than HCC. Inter-
estingly, benign entities such as sclerosing hemangiomata or abscesses can be misclassified 
as LR-M. As such, observations classified as LR-M require a core biopsy to obtain the histo-
logical diagnosis. High specificity is crucial for clinical practice in North America where liver 
transplantation is the treatment of choice for suitable patients with HCC. 
Focal liver lesions seen in patients without known malignancy or risk factors for HCC have 
a higher likelihood for benignity, with most of them being detected incidentally. A small 
proportion of these lesions can be malignant although the incidence of HCC in patients 
with no risk factors is very low (2). 
Ultrasound is commonly used for surveillance of HCC in cirrhotic patients; however, the 
characterization of focal liver lesions by ultrasound is limited. Multiphasic computed to-
mography (CT) or MRI is routinely performed for definitive imaging diagnosis of focal liver 
lesions. MRI is superior to CT in the evaluation of focal liver lesions due to lack of ionizing 
radiation, high contrast resolution and availability of hepatobiliary contrast agents (3). 
ABSTRACT 
Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are the most com-
mon primary liver malignancies.  HCC and ICC have characteristic imaging findings, but a num-
ber of benign entities can appear similar and can cause diagnostic dilemma. Ideally, accurate and 
timely diagnosis of these conditions can help the patient to avoid a needle biopsy or even un-
necessary treatment. In this article, we present various benign liver lesions that display imaging 
characteristics that are similar to HCC and ICC on magnetic resonance imaging (MRI) and discuss 
salient features that may assist in accurate diagnosis.
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This article reviews MRI features, which 
may assist in the differentiation of various 
benign focal liver lesions from HCC and ICC.
MRI with hepatobiliary  
contrast agents
Hepatocyte-specific, gadolinium-based 
(hepatobiliary) contrast agents are increas-
ingly being used in MRI studies of the liver. 
These agents are taken up and excreted by 
the hepatocytes of the liver via the organ-
ic anion-transporting polypeptide (OATP) 
group of molecules (in particular, OATP8) 
and multidrug resistance-associated pro-
teins (MRP)-2, respectively.
The hepatobiliary phase is obtained 10–20 
minutes after contrast injection with gadox-
etic acid (Gd-EOB-DTPA, Primovist in Europe 
and Asia; Eovist in the USA, Bayer) or after 
60–120 minutes in the case of Gadobenate 
dimeglumine (MultiHance, Bracco). In the 
hepatobiliary phase, malignant lesions that 
do not contain normal, functioning hepato-
cytes such as metastases, cholangiocarcino-
mas and HCC, are not expected to take up 
the contrast agent and will therefore show 
up as a hypointense defect against a back-
ground of hyperintense liver parenchyma. 
This increases sensitivity in the detection of 
metastasis and early HCC (4). 
However, benign lesions such as heman-
giomas, cysts and hepatic adenomas will 
also appear as a defect during the hepa-
tobiliary phase because they do not con-
tain functioning hepatocytes. Conversely, 
other benign lesions such as focal nodular 
hyperplasia (FNH) or nodular regenerative 
hyperplasia (NRH) contain normal function-
ing hepatocytes and will be hyperintense 
during the hepatobiliary phase (4). 
Mimickers of HCC
Arterioportal shunts
Arterioportal shunts (APS) are usually 
due to localized disordered perfusion and 
are common hypervascular pseudolesions 
that mimic HCC in the imaging of the cir-
rhotic liver (5, 6). 
No specific or discrete parenchymal ab-
normality is found on histopathology. The 
characteristic imaging features of APS are 
subcapsular or peripheral location, wedge-
shaped appearance and homogeneous 
enhancement in the hepatic arterial phase 
(Fig. 1). They are typically sub-centimeter in 
size. Differences in scan timing may result in 
the false impression that the lesion is new 
or is enlarging over time. MRI tends to be 
more sensitive for detection of APS, mainly 
due to the higher soft tissue contrast and 
consequently higher sensitivity for subcen-
timeter enhancing nodules. Key associated 
imaging features on MRI include absence 
of portovenous phase and/or equilibrium 
phase washout. These lesions are expect-
ed to show normal uptake of hepatobiliary 
contrast on MRI using gadoxetic acid since 
they are areas of differential perfusion but 
not impaired hepatocyte function (7). On 
unenhanced imaging, they usually show 
signal that is isointense to surrounding 
liver parenchyma, and no diffusion restric-
tion is seen. Since early HCC may display 
arterial phase hyperenhancement, atten-
tion to other features on MRI such as T2 
hyperintensity and restricted diffusion or 
for threshold growth over serial imaging 
becomes important (8). APS are benign and 
classified as either LR-1 or LR-2. Hence, care-
ful evaluation is required to avoid misclassi-
fying APS as an LR-4 observation. 
Hemangiomas
Hemangiomas are the most common focal 
benign liver lesion. They show characteris-
tic MRI features such as bright hyperintense 
signal on T2-weighted sequences, peripher-
al, discontinuous, nodular enhancement in 
the arterial phase with centripetal filling-in 
during the portal venous and delayed phases. 
Hemangiomas can sometimes be confused 
with HCC when gadoxetic acid is used as a 
contrast agent in the evaluation of patients 
with cirrhosis. Hemangiomas in cirrhotic liv-
ers tend to be smaller in size and show flash 
enhancement. Both HCC and small hemangi-
omas are hyperintense in the arterial phase. 
Progressed HCC is expected to have a wash-
out appearance in the portal venous and 
transitional phases. However, owing to the 
rapid uptake of gadoxetic acid by hepato-
cytes, flash enhancing hemangiomas may 
appear hypointense in the portal venous and 
transitional phases and thus may be misin-
terpreted as having a wash-out appearance 
(9) (Fig. 2). This would result in the erroneous 
diagnosis of HCC. Careful examination of the 
other MRI sequences is required in order to 
Main points
• Accurate characterization of benign mimics 
of HCC is important to avoid unnecessary 
biopsy or intervention, since HCC can be 
treated without histological confirmation 
when the characteristic imaging features are 
encountered in at risk patients.
• Arterial phase hyperenhancement with 
washout in subsequent phases is character-
istic of HCC and progressive enhancement is 
characteristic of cholangiocarcinoma. How-
ever, these enhancement characteristics are 
commonly encountered in nonmalignant 
lesions.
• T2 signal intensity, diffusion-weighted im-
aging and hepatobiliary contrast uptake are 
useful adjunct imaging features that, when 
interpreted alongside with multiphasic en-
hanced imaging, aid in differentiating benign 
from malignant entities.
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HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocarcinoma; FNH, focal nodular hyperplasia.
differentiate a flash enhancing hemangioma 
from HCC. Hemangiomas are very hyperin-
tense on T2-weighted sequences while HCC 
often show intermediate T2 signal. Further-
more, HCC shows restricted diffusion while 
hemangiomas will demonstrate T2 shine 
through. Alternatively, an extracellular con-
trast agent can be used (9, 10). 
Focal nodular hyperplasia
Focal nodular hyperplasia (FNH) is a com-
mon benign focal lesion of the liver. FNHs 
occur as a result of hyperplastic growth of 
normal hepatocytes but are characterized by 
a malformed biliary drainage. On MRI, FNHs 
are isointense to the liver on T1-weighted 
sequences and are mildly hyperintense on 
T2-weighted sequences. A central scar is 
seen in FNH, which is classically hyperintense 
on T2-weighted images, although this find-
ing is not always present. Following intra-
venous contrast administration, FNHs show 
brisk homogeneous arterial hyperenhance-
ment. The lesion subsequently becomes iso-
intense in the portal venous and transitional 
phases. On gadoxetic acid enhanced MRI, 
FNH characteristically shows intense and 
homogeneous uptake of contrast, appear-
ing hyperintense on the hepatobiliary phase 
(Fig. 3). The central scar, however, is depicted 
as hypointense on the hepatobiliary phase, 
given that it does not contain functioning 
hepatocytes. Just considering lesional arte-
rial hyperenhancement and the presence 
of a central scar, FNH can theoretically be 
mistaken for fibrolamellar HCC. However, 
fibrolamellar HCC shows T2 hypointense 
central scar and heterogeneous enhance-
ment (11). Approximately 20% of HCC show 
uptake of hepatobiliary contrast on delayed 
imaging and can therefore be mistaken for 
FNH (12–14). However, on dynamic imaging, 
FNHs do not display washout appearance, 
as opposed to HCC. FNH may show atypical 
hypointensity in hepatobiliary phase when 
there is substantial fat component or large 
radiating scar thus mimicking HCC (15). 
However, the arterial enhancement in FNH 
is typically homogeneous, while the arterial 
enhancement seen in HCC is usually hetero-
geneous with a mosaic or nodule-in-nodule 
appearance (16). 
Hepatic angiomyolipoma
Hepatic angiomyolipoma (HAML) is 
a benign tumor that contains varying 
amounts of fat, smooth muscle fibers and 
blood vessels (17). HAMLs are associated 
with tuberous sclerosis in less than 10% of 
cases. Patients with HAML are usually as-
ymptomatic, although some patients may 
present with vague abdominal discomfort 
or pain due to intratumoral hemorrhage. 
Due to the presence of fat within the lesion, 
HAMLs are hyperintense on T1-weighted 
sequences and loose signal following fre-
quency selective fat-suppression sequenc-
es. HAMLs also show relative signal loss on 
opposed phase sequences as compared 
to in-phase sequences due to the pres-
ence of intravoxel fat. Enhancement of the 
soft tissue elements is also seen following 
gadolinium base contrast media. However, 
50% of HAML do not have a substantial fat 
component. In such lipid-poor HAMLs, the 
enhancement of the soft tissue elements 
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Figure 2. a, b. Flash enhancing hemangioma in a 60-year-old woman with hepatitis B. Axial contrast-
enhanced arterial phase image (a) of the upper abdomen reveals a homogeneously enhancing 
lesion in the subcapsular region of segment 2 in the left lobe of the liver (arrow). Axial contrast-
enhanced image (b) of upper abdomen in hepatobiliary phase shows the corresponding lesion 
slightly hypointense to liver, thus mimicking HCC. However, bright hyperintensity of the lesion in T2-
weighted imaging (not shown) helped to accurately characterize it as flash enhancing hemangioma.
a b
Figure 1. a–c. Arterioportal shunt (APS) in a 48-year-old man with chronic hepatitis B. Axial contrast-enhanced magnetic resonance image (a) of the upper 
abdomen reveals a wedge shaped subcapsular, enhancing area (arrow) in the right lobe of the liver in the arterial phase. The corresponding area was 
isointense to the rest of the liver in T2-weighted image (b) and in venous phase (c). The characteristic location, morphology and enhancement pattern of 
the lesion is in keeping with APS.
a b c
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may be mistaken for arterial hyperenhance-
ment (18) (Fig. 4). More recently, it has been 
shown that HAMLs can be indistinguishable 
from HCC on the basis of enhancement pro-
files on gadoxetic acid enhanced MRI of the 
noncirrhotic liver (19). High grade dysplas-
tic nodules and early HCC may contain in-
tratumoral foci of fat, which can also show 
loss of signal on opposed phase images. 
These can often be followed up with serial 
close imaging. In some cases, needle biop-
sy or surgical resection may be required to 
establish the diagnosis. Patients with non-
alcoholic fatty liver disease (NAFLD) may 
develop steatohepatitic HCCs, which also 
contain macroscopic areas of fat and show 
arterial hyperenhancement, mimicking 
HAMLs. Hence, although HAMLs are con-
sidered benign entities, in areas where HCC 
and chronic liver disease is endemic, it may 
be prudent to biopsy fat containing liver 
lesions to exclude HCC, especially if they 
show threshold growth (20). 
Intrahepatic splenosis
Intrahepatic splenosis is a rare condition 
due to auto-transplantation of splenic tissue 
within the liver. It is thought to be due to 
implantation of splenic tissue into the liver 
secondary to trauma or surgery and, rarely, 
due to hematogenous spread (21). Intrahe-
patic splenosis is often confused with a pri-
mary hepatic nodule on imaging. It shows 
hyperenhancement in the arterial phase and 
subsequent de-enhancement, which may 
mimic HCC, especially if the patient has a his-
tory of chronic liver disease or hepatitis (22). 
Figure 3. a–c. Focal nodular hyperplasia (FNH) in a 46-year-old woman without chronic liver disease. Axial contrast-enhanced arterial phase image (a) 
of the upper abdomen shows a homogeneously enhancing lesion in right lobe of the liver (arrow). Axial contrast-enhanced images (b, c) of the upper 
abdomen show that the corresponding lesion becomes isointense to liver in the in venous phase (b, arrow) and retains contrast in the hepatobiliary 
phase (c, arrow). Note that the lesion retains contrast in the hepatobiliary phase, a key imaging finding in FNH that will help in differentiating it from 
non-hepatocyte-containing lesions. That said, uptake of hepatobiliary phase contrast can be seen in a minority of HCCs and FNH may show atypical 
hypointensity in hepatobiliary phase when it contains substantial fat and large central scar. Assessing washout on the portal phase would be key in the 
diagnosis of HCC.
a b c
Figure 4. a–d. Lipid-poor hepatic angiomyolipoma (HAML) in a 48-year-old woman without 
chronic liver disease. In-phase axial image (a) of the upper abdomen shows a well-defined, 
subcapsular lesion in segment VI in the right lobe of the liver (arrow). The lesion does not show 
loss of signal in out-of-phase image (b, arrow). Axial contrast-enhanced images (c, d) of upper 
abdomen show the corresponding lesion enhancing in the arterial phase (c, arrow) and seen as a 
defect in the hepatobiliary phase (d, arrow). The enhancement characteristics mimic hepatoma; 
however, there are no risk factors for HCC in this patient. The lesion was finally proven to be lipid-





However, intrahepatic splenules mirror the 
signal intensity of the spleen on all sequenc-
es. Furthermore, HCCs will have a washout 
appearance. Hence, intrahepatic splenosis is 
a differential diagnosis that should be kept 
in mind when an arterially enhancing intra-
hepatic lesion is encountered in a patient 
with previous splenic trauma or splenecto-
my (Fig. 5). Nuclear scintigraphy using tech-
netium-99m (99mTc) labeled heat denatured 
erythrocytes is a useful imaging test that can 
be used to confirm the diagnosis of intrahe-
patic splenosis (23). 
Benign intrahepatic lymphoid nodule
Benign intrahepatic lymphoid nodules are 
also known as pseudolymphomas. These are 
rare, benign lesions, characterized by prolif-
eration of polyclonal lymphocytes forming 
follicles with an active germinal center. Pa-
tients with such lesions are usually asymp-
tomatic and are incidentally detected on 
cross-sectional imaging. Only 51 cases have 
been reported in English literature (24). Ac-
cording to  a review of 9 histologically prov-
en pseudolymphomas by Yoshida et al. (25), 
pseudolymphomas show increased T2 signal, 
are hypointense on T1-weighted sequences 
and demonstrate restricted diffusion. These 
lesions also show arterial hyperenhancement 
with wash-out appearance. Furthermore, 
they present as a defect on the hepatobili-
ary phase on gadoxetic acid enhanced MRI. 
These imaging features can be very similar 
to HCC and hypervascular metastases (Fig. 
6a–6c). Understandably, it is easy to mistake 
pseudolymphomas for a malignant liver 
tumor on imaging. However, even in the 
presence of characteristic features of arteri-
al phase hyperenhancement and washout 
appearance, in patients with no history of 
chronic liver disease, the imaging diagnosis 
of HCC cannot be made and a biopsy is man-
dated. Histologically, pseudolymphomas 
consist of marked lymphoid follicles and ger-
minal centers with no significant atypia (Fig. 
6d) (24–26).
Hepatocellular adenoma
Hepatocellular adenoma (HCA) is a be-
nign liver tumor that predominantly occurs 
in young and middle-aged women with his-
tory of oral contraceptive intake. Inflamma-
tory, hepatocyte nuclear factor-1α-mutat-
ed, β-catenin-mutated, and unclassified are 
the four subtypes of HCA. The imaging find-
ings of HCA may vary according to the sub-
type and presence of complications such as 
hemorrhage. HCA characteristically shows 
mild T2 hyperintensity, arterial phase en-
hancement, washout in the venous phase, 
and appear as a defect in the hepatobiliary 
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Figure 5. a–c. Intrahepatic splenosis in a 56-year-old man with previous history of splenic injury. T1-weighted axial image (a) of the upper abdomen 
shows a nodular T1 hypointense focus in the left lobe of the liver (arrow). Axial contrast-enhanced images (b, c) of the upper abdomen show the 
corresponding focus enhancing similar to spleen in portal venous phase (b, arrow) and seen as a defect in the hepatobiliary phase (c, arrow). There is a 
history of splenic injury and the lesion is similar to the remnant spleen (arrowhead) in all pulse sequences; these are key to the diagnosis.
a b c
Figure 6. a–d. Benign intrahepatic lymphoid nodule in a 51-year-old woman without chronic 
liver disease. Axial contrast-enhanced images (a–c) of the upper abdomen show the lesion 
(arrow) enhancing in the arterial phase (a), washing out in the portal venous phase (b) displaying 
a capsule appearance, and as a filling defect in the hepatobiliary phase (c). Based on the 
enhancement characteristics, possibility of malignant mass such as HCC was considered, but 
absence of risk factors caused a diagnostic dilemma; the patient opted for excision biopsy, which 
proved the lesion to be benign intrahepatic lymphoid nodule. Photomicrograph (d) (original 
magnification, ×40; hematoxylin-eosin [H-E] stain) higher power view shows reactive secondary 
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phase thus mimicking HCC (Fig. 7). Useful 
imaging findings of HCA that may help in 
differentiation from HCC include presence 
of large amounts of fat, a band of periph-
eral T2 hyperintensity (atoll sign) (Fig. 7a), 
and occurrence in a noncirrhotic liver (27, 
28). With extracellular contrast agents HCA 
can be confused with FNH, as both are hy-
perenhancing benign lesions and occur in a 
similar population group; however, hepato-
biliary contrast agents will help in differen-
tiation, as HCA will appear hypointense to 
liver in the hepatobiliary phase, while FNH 
will appear hyper- or isointense to back-
ground liver (29) (Fig. 7d). 
Mimickers of ICC
Sclerosing hemangioma
Sclerosed or sclerosing hemangioma is 
a rare variant and it develops as a result 
of extensive hyalinization of an existing 
hemangioma. The pathogenesis of scle-
rosing hemangiomas is not well studied 
but thought to be due to hemorrhage or 
thrombosis within the hemangioma, re-
sulting in fibrosis and eventually leading 
to sclerosing hemangioma. Histologically, 
sclerosing hemangiomas are character-
ized by extensive fibrosis and hyaliniza-
tion with narrowing and obliteration of 
the vascular spaces. The extent of sclero-
sis and hyalinization may vary, depend-
ing on the degree of fibrosis that has 
occurred (30). Sclerosing hemangiomas 
can show irregular rim enhancement and 
patchy central enhancement in the early 
phases of contrast-enhanced CT or MRI. 
The atypical enhancement pattern seen 
in sclerosing or sclerosed hemangiomata 
could be attributed to the heterogeneity 
of fibrosis and the degree of hyaline scle-
rosis occurring within the lesion. Patchy 
enhancement of the sclerosing hemangi-
oma in the hepatic arterial phase can be 
mistaken for the arterial hyperenhance-
ment seen in HCC. Imaging findings of 
sclerosing hemangioma that can be use-
ful to differentiate it from HCC are capsu-
lar retraction, decrease in size over time, 
presence of transient hepatic attenuation 
difference, loss of previously seen regions 
of enhancement at follow-up and absence 
of washout in the delayed phase (31, 32). 
While capsular retraction and absence of 
washout in the delayed phase help in dif-
ferentiating it from HCC, the downside is 
that it can be potentially confused with 
ICC (33) (Fig. 8). On T2-weighted MRI, scle-
rosing hemangiomas tend to show het-
erogeneously lower signal intensity than 
Figure 7. a–d. Hepatocellular adenoma (HCA) in a 44-year-old woman with no risk factors for HCC. 
Axial T2-weighted image (a) of the upper abdomen shows a mild T2 hyperintense lesion in the right 
lobe of the liver with peripheral hyperintense rim (atoll sign) (a, arrow). Axial contrast-enhanced 
arterial phase image (b) of the upper abdomen shows a homogeneously enhancing lesion in the 
right lobe of the liver (arrow). Axial contrast-enhanced images (c, d) of the upper abdomen show 
the corresponding lesion washed out in venous phase (c, arrow) and hypointense to liver in the 
hepatobiliary phase (d, arrow), thus mimicking HCC. Note that the lesion does not retain contrast in 




Figure 8. a–c. Sclerosing hemangioma in a 58-year-old woman without chronic liver disease. Axial T2-weighted fast spin-echo image of the upper 
abdomen (a) shows a mild T2 hyperintense lesion in the right lobe of the liver (arrow). Axial images of upper abdomen after administration of gadoterate 
meglumine show the corresponding region minimally enhancing in the arterial phase (b, arrow) and progressively enhancing in the delayed phase (c, 
arrow). The findings were inconsistent with a classic hemangioma, and the diagnosis of a malignant primary lesion such as ICC needed to be excluded. 
a b c
other hemangiomas. However, the signal 
intensity is still higher than expected in 
most malignancies (31). 
Inflammatory pseudotumor
Inflammatory pseudotumor (IPT) of the 
liver is a rare benign lesion due to chron-
ic inflammation and fibroblast prolifera-
tion. Patients usually present with symp-
toms of fever and abdominal pain (34). 
Infection and autoimmune diseases are 
associated with IPT of the liver (34). Few 
studies have reported that hepatopancre-
atobiliary autoimmune diseases, such as 
IgG4 sclerosing cholangitis can cause IPT 
of the liver (35). An increased incidence 
of IPT is encountered in patients with re-
current pyogenic cholangitis (36). IPT can 
be confused with malignant liver tumors 
and hepatic abscess on imaging (37). This 
is due to the varied enhancement pattern 
of IPT. IPTs have been described to show 
heterogeneous or peripheral enhance-
ment in the arterial phase, progressive en-
hancement or washout appearance in the 
delayed phase (34, 37) (Fig. 9). As such, it 
is difficult to differentiate IPT of liver from 
more aggressive lesions like HCC and ICC 
on imaging alone, particularly in a patient 
with chronic liver disease. Typically, biopsy 
is necessary to obtain a definitive diagno-
sis (38). 
Bile duct adenoma
Bile duct adenoma (BDA) is a rare benign 
focal liver lesion. It arises from the bile duct 
epithelium secondary to trauma or inflam-
mation (39). The reported incidence of bile 
duct adenoma is 1.3% among benign pri-
mary liver tumors (40). BDA is detected inci-
dentally during imaging, surgery or during 
autopsy. It is usually a solitary, subcapsular, 
solid lesion, less than 2 cm in size (39). On 
MRI it may appear hyper- or hypointense 
in T2-weighted image. It usually shows 
enhancement in the arterial and venous 
phases. Enhancement may be observed in 
delayed images, depending on the degree 
of fibrosis (41) (Fig. 10). BDAs also appear 
as a defect in the hepatobiliary phase on 
gadoxetic acid enhanced MRI and thus 
may be confused with HCC. However, the 
lack of diffusion restriction in BDA can po-
tentially help in differentiating it from HCC 
(42). Histologically, BDA is characterized by 
inflammation, fibrosis, and proliferation of 
bile ductules usually reactive to focal inju-
ry and may be associated with chronic liver 
disease (39). 
Conclusion 
Various benign conditions in the liver 
can show imaging features similar to HCC 
and ICC. The recognition of the character-
istic MRI findings of various benign lesions 
is pertinent to avoid false-positive diagno-
sis of HCC or ICC and subsequent unnec-
essary invasive management. A careful 
imaging approach along with a review 
of clinical and histopathological findings 
is helpful in differentiating these lesions 
from HCC and ICC. 
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Figure 9. a–c. Inflammatory pseudotumor in a 70-year-old man with constitutional symptom and no risk factors for HCC. Axial contrast-enhanced image 
of the upper abdomen in arterial phase (a) shows a rim enhancing lesion in the right lobe of liver (arrow). Axial contrast-enhanced images (b, c) of upper 
abdomen show the corresponding lesion with progressive enhancement in portal venous (b, arrow) and delayed phase (c, arrow) images. Note minimal 
right pleural effusion and right basal atelectasis. Presence of constitutional symptoms and absence of risk factors were against the diagnosis of malignant 
liver lesions such as ICC and a close follow-up or biopsy was advised. The lesion regressed on follow-up studies (not shown) and presumed to be due to 
spontaneous regression of IPT. 
a b c
Figure 10. a–c. Bile duct adenoma in a 49-year-old man. Axial contrast-enhanced images (a, b) of upper abdomen show rim enhancing subcapsular lesion 
in the arterial phase (a, arrow) and central enhancement of the lesion in the venous phase (b, arrow) in the right lobe of the liver. Resected liver segment 
(c) shows solitary, subcapsular lesion in right lobe of the liver (arrow). The lesion was proven to be a bile duct adenoma by histopathological examination 
(not shown). 
a b c
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